BiotechTube
Arrivo BioVentures

Arrivo BioVentures

Raleigh, United States· Est.
arrivobio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $90.3M

Overview

Arrivo BioVentures, founded in 2018 and based in Raleigh, NC, is a private biotech holding company with a portfolio of two clinical-stage drug candidates acquired through licensing and partnerships. The company leverages an experienced management team with a strong track record in fundraising and exits to advance novel therapies for major depressive disorder (SP-624) and predicted severe acute pancreatitis (RABI-767). Its strategy centers on in-licensing and developing disease-modifying therapies with new mechanisms of action for conditions with high unmet need.

PsychiatryGastroenterologyCritical Care

Technology Platform

Asset-centric business model focused on in-licensing late-stage clinical candidates with novel mechanisms of action and providing strategic oversight, funding, and development execution.

Funding History

3
Total raised:$90.3M
Series B$45.3M
Series A$35M
Seed$10M

Opportunities

The large, underserved market for Major Depressive Disorder presents a multi-billion dollar opportunity for a novel, effective therapy like SP-624.
For RABI-767, there is a critical unmet need in preventing Severe Acute Pancreatitis, a condition with no approved specific treatment, offering potential for a high-value, niche breakthrough therapy and standard of care.

Risk Factors

High clinical development risk as both lead programs are unproven in late-stage trials.
Financial risk is significant as the pre-revenue company is dependent on external capital raises to fund expensive clinical studies.
Intense competition in the depression market and the need to prove a dramatic benefit in pancreatitis pose substantial commercial and clinical hurdles.

Competitive Landscape

In Major Depressive Disorder, SP-624 faces intense competition from both established antidepressants and a pipeline of novel mechanisms from large pharma and biotech. For RABI-767 in acute pancreatitis, the competitive field is less crowded but still includes other investigational approaches; success hinges on demonstrating clear superiority in preventing severe progression where no specific pharmacologic therapy currently exists.

More companies in Biologics / Biosimilars →More companies in United States →